by 
Frasier syndrome, also known as FS, is a rare inherited disorder caused by pathogenic variants in the WT1 gene. The symptoms of this syndrome include genitourinary abnormalities in males as well as a higher risk of developing kidney cancer. Treatment focuses on managing individual symptoms and includes procedures like renal transplantation. With no approved drug therapies currently available, the management of FS poses a challenge. However, growing efforts to increase awareness about rare diseases has put the spotlight on this complex condition.
The global Frasier Syndrome Market is estimated to be valued at US$ 141.2 Mn in 2023 and is expected to exhibit a CAGR of 5.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the major trends in the Frasier Syndrome market is the increasing research on drug development. Several biotech and pharmaceutical companies are conducting clinical trials to identify potential drug candidates for treating this rare disease. For instance, ObsEva SA is evaluating the safety and efficacy of linzagolix in children and adolescents with FS or Denys-Drash syndrome. Another key manufacturer, Pfizer Inc., is sponsoring a study to understand the natural history and disease burden of FS to help accelerate drug development efforts. Such ongoing research and collaborations aimed at developing the first approved therapies bode well for market growth over the coming years.
Porter’s Analysis
Threat of new entrants: Low barriers to entry as gene therapy is an evolving field with opportunities for new players.
Bargaining power of buyers: Patients have limited choice of treatments available and rely on suppliers.
Bargaining power of suppliers: Suppliers like drug makers hold strong positions due to patented drugs and therapies with few alternatives available.
Threat of new substitutes: Limited substitutes currently available for Frasier Syndrome treatment pose a low threat from new substitutes.
Competitive rivalry: Intense competition exists among existing players to develop newer and improved therapies.
Key Takeaways
The global Frasier Syndrome market is expected to witness high growth.
Regional analysis: North America is projected to dominate the Frasier Syndrome market during the forecast period owing to growing awareness and rising healthcare expenditure. Europe is also expected grow at a significant rate due to advancement in gene therapy research.
Key players: Key players operating in the Frasier Syndrome market are Denali Therapeutics, Arcturus Therapeutics, CENTOGENE N.V., Genome & Company, Khondrion among others. Denali Therapeutics is a leading player focused on developing treatment for genetically defined diseases. Arcturus Therapeutics is engaged in the development of messenger RNA medicines.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
